ALK and non-small cell lung carcinoma: These results suggest that combining WBRT with cytotoxic chemotherapy could be beneficial for survival in NSCLC patients who are EGFR, ALK, and PD-L1 negative, have an ECOG PS of 2, and have multiple metastases including brain metastases.